FENC FENNEC PHARMACEUTICALS INC.

8-K Current Report

Filed: March 16, 2026

Health Care

Biological Products, (No Diagnostic Substances)

FENNEC PHARMACEUTICALS INC. (FENC) 8-K current report filed with SEC EDGAR on March 16, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 8.01: Other Events

AI Filing Analysis
8-K

Item 8.01 · Other Events

• Settlement with Cipla grants PEDMARK® exclusivity protection through September 1, 2033, blocking generic sodium thiosulfate entry
• License Agreement resolves patent litigation (D.N.J. Case No. 2:23-cv-00123) — no damages or royalties mentioned, each party bears own costs

+2 more insights

Other FENNEC PHARMACEUTICALS INC. 8-K Filings

8-K Mar 4, 2026

Get deeper insights on FENNEC PHARMACEUTICALS INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.